Phase II Study Alimta and Gemzar + Avastin as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV NSCLC
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine the progression free survival with pemetrexed, and
gemcitabine plus bevacizumab as first-line chemotherapy in elderly patients with Stage
IIIB/IV non-small cell lung cancer (NSCLC).
The secondary objectives are to determine the overall response rate; overall survival;
chemotherapy induced toxicity profile of this combination; time to progression; and patient
reported symptom burden.